Compare Crispr Therapeutics AG (CRSP) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ArcelorMittal SA — how do they compare? Crispr Therapeutics AG trades at $50.76 (market cap $4.97B), while ArcelorMittal SA trades at $66.94 (market cap $50.59B). The key difference: ArcelorMittal SA is far larger — about 10.2× Crispr Therapeutics AG's market cap, and ArcelorMittal SA pays a 0.9% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MT | |
|---|---|---|
Market Cap | $4.97B | $50.59B |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $71.65 |
52-Week Low | $44.34 | $30.39 |
Enterprise Value | $3.32B | $59.91B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
ArcelorMittal (MT) trades at $65.92, down 0.24% today, with a bullish technical outlook and strong recent earnings beats. The stock shows robust fundamentals with a P/E of 17.26 and P/S of 0.81, supported by a net income margin of 4.71% and consistent dividend payments. Recent news highlights expansion initiatives and a strategic AI collaboration with AWS, driving positive sentiment amid a 41% six-month gain (Zacks Investment Research, 2026-06-23).
Outlook remains positive with analyst consensus at 50% buy ratings, though risks include cyclical steel demand and high capital expenditure. The stock's valuation appears reasonable, but investors should monitor global economic conditions and steel pricing trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
